TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026

TScan Therapeutics, Inc.

2023-Q3 EPS reported -$1.25 revenue$13,838,000

Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.
Cash, equivalents, and marketable securities $215.4M as of Sept 30; funding operations into 2026.
FDA cleared IND for TSC-203-A0201 targeting PRAME; plans to file two additional INDs by year-end.
Expects initial heme program data at ASH Dec 2023; solid tumor Phase 1 enrollment by year-end 2023.
R&D expenses $22.7M, up $7.7M YoY due to clinical start-up costs and personnel expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.